Le Lézard
Classified in: Health, Covid-19 virus
Subjects: NPT, AVO

Tuberculosis and COVID-19: Stop TB USA Calls for Strengthening Public Health Programs to Fight Co-Pandemics


ATLANTA, July 21, 2020 /PRNewswire/ -- America and the world may be ill-prepared to fight concurrent global pandemics in COVID-19 and tuberculosis (TB) ? both largely airborne infectious diseases and significant public health threats.  Stop TB USA, a coalition committed to TB elimination, is calling for strengthening public health programs to fight the co-pandemics. 

The coronavirus response is placing an extra burden on already underfunded TB programs as specialists are tapped to teach contact tracing ? a public health tactic recognized by the CDC as essential to stopping the chain of transmission of highly infectious disease.  The practice has been a pillar of TB programs for more than a century and is crucial to pushing COVID-19 and TB curves downward.

"In Los Angeles County, our TB team supports contact tracing both with training and sometimes execution, even as TB resources are already stretched," says Julie M. Higashi, MD, PhD, President, National Tuberculosis Controllers Association.  "While it's important to support the COVID-19 response, we don't want to lose ground on TB elimination. In public health, we know first-hand that none of us are safe until all of us are safe."

Historically, TB has hurt low-income Americans, and restricted travel limits their access to TB diagnosis and treatment. Now these individuals are at increased risk for coronavirus transmission due to difficulties practicing social distancing and work in essential jobs outside their homes. There also is concern that COVID-19 could have serious medical effects on TB patients as both diseases often attack the respiratory system. 

"The Colorado Department of Public Health TB program has been cut by 4% at a time when we're already working on the coronavirus response," says Randall Reves, MD, Professor of Medicine, University of Colorado School of Medicine.  "We are living in challenging times and it's important for all in public health to contribute.  Yet, fighting two pandemics at once is having a negative impact on TB diagnosis and treatment, and a cut in funding will only make matters worse."

TB programs across the country are reporting budget cuts.  Stop TB USA appeals to the public and lawmakers to ensure that the TB programs continue, without interruption.  Increased funding is needed to strengthen efforts to identify, treat and prevent TB, including drug resistant strains and latent TB infection.  TB is the leading infectious disease killer worldwide with 1.5 million people dying annually.

SOURCE Stop TB USA


These press releases may also interest you

at 05:45
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to  ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution...

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...



News published on and distributed by: